{"entity":{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","aka":["Qilu Pharmaceutical Co., Ltd."],"tldr":"Qilu Pharmaceutical is a China-based pharmaceutical company running 20 late-stage cancer trials of QL1706, QLC5508 and QL2107 in non-small-cell lung cancer, oesophageal cancer and triple-negative breast cancer.","summary":"Qilu Pharmaceutical, based in Jinan, China, is a pharmaceutical company. Qilu Pharmaceutical is a large Chinese pharmaceutical manufacturer that develops and produces innovative drugs, biosimilars, improved new drugs and generic medicines across oncology, cardiovascular, anti-infection and ophthalmology, among other areas. On ClinicalTrials.gov it is the lead sponsor of 20 recruiting or active phase 2 and phase 3 interventional cancer trials (13 in phase 3), testing QL1706, QLC5508, QL2107, QL0911 and ESG401 in non-small-cell lung cancer, oesophageal cancer, triple-negative breast cancer, multiple myeloma and HR-positive / HER2-negative breast cancer. The largest, NCT06754644 (A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC), plans to enrol 808 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.qilu-pharma.com"},{"label":"ClinicalTrials.gov: trials led by Qilu Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Qilu%20Pharmaceutical%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","esophageal","tnbc","multiple-myeloma","breast-hr-positive","prostate","colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["qlc5508","ql1706","ql2107","esg401","qls32015","qls31905","qlh12016","iruplinalkib","iparomlimab-tuvonralimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07018050","nct07198633","nct06994507","nct07102004","nct07724756","nct06911827","nct07256782","nct07235176"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Jinan","country":"CN","companyType":"pharma","website":"https://www.qilu-pharma.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/qilu-pharmaceutical/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"esg401","kind":"drug","name":"ESG401","route":"/drugs/esg401/"},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"},{"id":"iruplinalkib","kind":"drug","name":"Iruplinalkib","route":"/drugs/iruplinalkib/"},{"id":"ql1706","kind":"drug","name":"QL1706","route":"/drugs/ql1706/"},{"id":"ql2107","kind":"drug","name":"QL2107","route":"/drugs/ql2107/"},{"id":"qlc5508","kind":"drug","name":"QLC5508","route":"/drugs/qlc5508/"},{"id":"qlh12016","kind":"drug","name":"QLH12016","route":"/drugs/qlh12016/"},{"id":"qls31905","kind":"drug","name":"QLS31905","route":"/drugs/qls31905/"},{"id":"qls32015","kind":"drug","name":"QLS32015","route":"/drugs/qls32015/"}],"trial":[{"id":"nct07502014","kind":"trial","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line","route":"/trials/nct07502014/"},{"id":"nct07198633","kind":"trial","name":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","route":"/trials/nct07198633/"},{"id":"nct06383767","kind":"trial","name":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06383767/"},{"id":"nct06732323","kind":"trial","name":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06732323/"},{"id":"nct07802821","kind":"trial","name":"A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm","route":"/trials/nct07802821/"},{"id":"nct07138209","kind":"trial","name":"A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07138209/"},{"id":"nct04641754","kind":"trial","name":"A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer","route":"/trials/nct04641754/"},{"id":"nct06954246","kind":"trial","name":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06954246/"},{"id":"nct06686576","kind":"trial","name":"A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct06686576/"},{"id":"nct05487391","kind":"trial","name":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection","route":"/trials/nct05487391/"},{"id":"nct05690945","kind":"trial","name":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","route":"/trials/nct05690945/"},{"id":"nct06789796","kind":"trial","name":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy","route":"/trials/nct06789796/"},{"id":"nct07256782","kind":"trial","name":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","route":"/trials/nct07256782/"},{"id":"nct06911827","kind":"trial","name":"A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients","route":"/trials/nct06911827/"},{"id":"nct07079228","kind":"trial","name":"A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer","route":"/trials/nct07079228/"},{"id":"nct06754644","kind":"trial","name":"A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC","route":"/trials/nct06754644/"},{"id":"nct07151872","kind":"trial","name":"Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer","route":"/trials/nct07151872/"},{"id":"nct06994507","kind":"trial","name":"GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer","route":"/trials/nct06994507/"},{"id":"nct07162883","kind":"trial","name":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07162883/"},{"id":"nct07235176","kind":"trial","name":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients","route":"/trials/nct07235176/"},{"id":"nct07724756","kind":"trial","name":"Phase II Study of QLC2519 in Pediatric Solid Tumor Participants","route":"/trials/nct07724756/"},{"id":"nct07018050","kind":"trial","name":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","route":"/trials/nct07018050/"},{"id":"nct07416058","kind":"trial","name":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","route":"/trials/nct07416058/"},{"id":"nct07025239","kind":"trial","name":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","route":"/trials/nct07025239/"},{"id":"nct07463573","kind":"trial","name":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","route":"/trials/nct07463573/"},{"id":"nct07453394","kind":"trial","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07453394/"},{"id":"nct04632758","kind":"trial","name":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct04632758/"},{"id":"nct07102004","kind":"trial","name":"Study of MHB088C for Patients With Advanced Solid Malignant Tumors","route":"/trials/nct07102004/"}]}}